Navigation Links
Apexigen Secures $20 Million Series A1 Financing
Date:8/6/2013

BURLINGAME, Calif., Aug. 6, 2013 /PRNewswire/ -- Apexigen Inc., a biopharmaceutical company dedicated to discovering and developing innovative antibody-based drugs for the treatment of serious diseases, announced today that it has secured $20 million in Series A1 financing.  The funding will be used to advance the development of APX005, an immunotherapeutic for the treatment of cancers, and to support the development of additional pipeline programs.

"We are very pleased and gratified by the response and support from our investors. The level of interest and enthusiasm in Apexigen, as seen in the oversubscription rate, provides a significant vote of confidence in our progress to-date and in our prospects going forward" said Xiaodong Yang, MD, PhD, President & CEO of Apexigen. "This financing provides us the financial strength to complete the transition from start-up mode toward a focus on the development of innovative new therapeutics."

"The board is clearly delighted to have secured this strategic financing which is one more demonstration of the remarkable execution by the management team" said Kenneth Fong, Chairman of the Board.

Since its founding in 2010 Apexigen has advanced its lead program APX005 and built a network of partnerships which broadens the use of its proprietary monoclonal antibody technology platform and advances the development of its pipeline product candidates.  Four new corporate partnerships have been established and 4 INDs have been filed for products developed utilizing Apexigen's proprietary technologies; 2 of those products are currently in Phase 1 testing by Apexigen's partners.

APX005 is a promising immunotherapeutic capable of destroying tumor and tumor stroma through several distinct mechanisms of action.  APX005 is a strong CD40 agonist that can stimulate anti-tumor immune response
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
2. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
3. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
4. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. Real Time Genomics Secures a $5 Million Round of Funding to Expand Commercial Operations
7. - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -
8. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
9. Nabsys Secures $20 Million Series D Financing to Support Launch of Semiconductor-Based Single-Molecule Platform for Genomic Analysis
10. Unisense FertiliTech A/S Secures an Additional 20 Million USD in New Capital Investment
11. Blue Marble Biomaterials Secures Distribution Agreement with SAFC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago this year, ... Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. The Academy ... Participants will have the opportunity to build a Free Flight fantasy club worthy of ...
(Date:7/23/2015)... ... 23, 2015 , ... July 23, 2015, Chicago - Advances ... options with fewer side effects, according to Erik P. Sulman, MD, PhD, associate ... the American Brain Tumor Association (ABTA) National Patient and Family Conference in Chicago, ...
(Date:7/23/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian ... Limited (Biohaven), are pleased to announce that Biohaven ... with the U.S. Food and Drug Administration (FDA) ... 54% equity interest in Biohaven, a private company. ... and Biohaven has entered into an exclusive worldwide ...
(Date:7/23/2015)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... and the general public to its Annual Shareholder Meeting ... 31, 2015. The meeting will be held at the ... San Diego, California 92121.   ... available. Please use the following link to register for ...
Breaking Biology Technology:Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4OncoSec to Webcast Annual Meeting of Stockholders 2
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
... using LipoTAXI transfection reagent , Peter ... Karmiol ,Clonetics Corporation, Walkersville, Maryland , LipoTAXI ... that offers,low cellular toxicity and high transfection ... is described for optimizing the amounts of ...
... transfection reagent: A proven choice , ... transfection reagent offers,improved, ... growing in,suspension. In this article, we summarize the ... LipoTAXI reagent. Optimizing transfection,conditions is a critical, preliminary ...
Cached Biology Technology:Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 2Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 4Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 2Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 3Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 6Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 7
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... natural selection favours traits that enhance dispersal of ... this theory, however, is relatively scarce. A study ... Biological and Environmental Sciences of the University of ... evolution of traits facilitating dispersal in an outer ...
... much iron is toxic, and can cause fatal organ failure. ... also be maintained. In a study published today in ... (EMBL) in Heidelberg, Germany, have discovered that a group of ... and as such are essential for cell survival. More specifically, ...
... ANN ARBOR, Mich.---In one of the first human studies ... the controversial chemical Bisphenol A, or BPA, may be related ... the researchers are quick to point out that these results ... documented adverse effects of BPA on semen in rodents, but ...
Cached Biology News:UH: Insular evolution: Large and big-footed voles in an outer archipelago 2Supply and demand 2Sperm may be harmed by exposure to BPA, study suggests 2
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
, Glycerol 30%...
Biology Products: